Health · Medical Research · 2 hrs ago
Early trials suggest CBL-514 injection reduces body fat
CBL-514 is an experimental injection designed to kill some fat cells, rather than simply shrink them.
In two phase 2 trials, the treatment reduced fat beneath the skin in most participants.
An analysis of 41 participants found an average 12.01% reduction in abdominal fat around organs after treatment, while the placebo group’s average increased.
These findings are preliminary and have not been peer-reviewed, so they need confirmation in larger studies.
In rats, adding CBL-514 to the weight-loss drug tirzepatide led to greater weight loss and less regain after treatment stopped than tirzepatide alone.
That result does not show the combination works in people, and researchers say further human testing is needed.
Larger trials will assess whether the fat loss lasts and is safe, including whether it affects fat storage in other organs or blood sugar and fat levels.
Early clinical trials suggest that injected CBL-514 can reduce subcutaneous fat, while an analysis of a small participant group found a reduction in visceral fat.
The treatment works by killing a subgroup of fat cells rather than shrinking them.
In the analysis of 41 participants, those given CBL-514 had an average 12.01 percent reduction in visceral fat, while the placebo group had an average 5.68 percent increase.
Animal tests found that rats given CBL-514 with tirzepatide lost more weight and regained less after treatment stopped than rats given tirzepatide alone.
The results have not been peer-reviewed, and researchers say larger trials and longer follow-up are needed.
- Who
- Researchers studying CBL-514, including trial leader Timothy Garvey, reported the findings.
- What
- Early trial results suggest injected CBL-514 reduces fat, including subcutaneous fat and possibly visceral fat.
- When
- The results were reported in October 2026; participants received injections for up to 12 weeks.
- Where
- The trials’ locations are Not stated. The visceral-fat analysis concerned the abdominal region.
- Why
- Researchers are investigating whether CBL-514 could reduce body fat and potentially complement GLP-1 drugs; its effects and safety need further study.
This story does not have two clearly opposing sides.
Trials CBL-0204 and CBL-0205 involved 107 and 173 participants and found CBL-514 reduced subcutaneous fat in most volunteers.
Researchers analyzed records from a subset of 41 participants for changes in visceral fat.
Participants given CBL-514 injections had an average 12.01 percent reduction in visceral fat.
Rats given tirzepatide and CBL-514 lost more weight and regained less after tirzepatide stopped than rats given tirzepatide alone.
- Drug
- CBL-514, administered by injection
- Phase 2 trial CBL-0204
- 107 participants
- Phase 2 trial CBL-0205
- 173 participants
- Visceral-fat analysis
- 41 participants
- CBL-514 group
- Average 12.01 percent visceral-fat reduction
- Placebo group
- Average 5.68 percent visceral-fat increase four weeks after the final injection
What people are saying
We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss
Larger trials with longer follow-up will be important to establish whether the fat reduction lasts and whether it leads to improvements in health.
To be a useful obesity therapy it will be critical to show that this doesn't increase the risk of fat accumulation in other organs or poorer control of blood fat and sugar levels